Seres Therapeutics, Inc.MCRBEarnings & Financial Report
Seres Therapeutics is a clinical-stage biotechnology company focused on developing novel microbiome-based therapeutic medicines. It targets unmet needs across infectious, inflammatory, and metabolic disease areas, with lead candidates for recurrent Clostridioides difficile infection. It operates primarily in the U.S. and partners with global pharma firms to advance its pipeline.
MCRB Q3 FY2025 Key Financial Metrics
Revenue
$351.0K
Gross Profit
N/A
Operating Profit
$-22.5M
Net Profit
$8.2M
Gross Margin
N/A
Operating Margin
-6403.7%
Net Margin
2337.3%
YoY Growth
N/A
EPS
$0.94
Seres Therapeutics, Inc. Q3 FY2025 Financial Summary
Seres Therapeutics, Inc. reported revenue of $351.0K for Q3 FY2025, with a net profit of $8.2M (down 90.8% YoY) (2337.3% margin).
Key Financial Metrics
| Total Revenue | $351.0K |
|---|---|
| Net Profit | $8.2M |
| Gross Margin | N/A |
| Operating Margin | -6403.7% |
| Report Period | Q3 FY2025 |
Seres Therapeutics, Inc. Annual Revenue by Year
Seres Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2024 revenue was $0).
Seres Therapeutics, Inc. Quarterly Revenue & Net Profit History
Seres Therapeutics, Inc. results over the last 5 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q3 FY2025 | $351.0K | — | $8.2M | 2337.3% |
| Q4 FY2024 | $0 | — | N/A | N/A |
| Q3 FY2024 | $0 | — | $88.8M | N/A |
| Q2 FY2024 | $0 | — | $-32.9M | N/A |
| Q1 FY2024 | $0 | — | $-40.1M | N/A |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $351000 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|
| Assets | $341.3M | $321.7M | $178.7M | $139.8M | $143.5M |
| Liabilities | $401.0M | $408.8M | $154.8M | $126.0M | $99.8M |
| Equity | $-59.7M | $-87.1M | $23.9M | $13.8M | $43.7M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q3 2025 | |
|---|---|---|---|---|---|
| Operating CF | $-35.2M | $-39.8M | $-34.7M | $-148.6M | $2.2M |